

Picture Stories

A case of congenital chylothorax

*Thilina Madushanka Munasinghe¹, Chamidri Naotunna¹, Samitha Danansooriya¹, Kalpana Hettiarachchi¹, Imalke Kankanarachchi², Ganga Hapuarachchi³, Kaushalya Gomez³, Ganganath Gunathilaka¹, Aruna De Silva²

Sri Lanka Journal of Child Health, 2019; 48(3): 275-276

DOI: <http://dx.doi.org/10.4038/sljch.v48i3.8770>

(Key words: Chylothorax, congenital)

Introduction

Chylothorax is the commonest cause of pleural effusion encountered during the perinatal period¹. Congenital chylothorax (CC) is rare with a prevalence of 1:10,000¹. CC could be due to congenital lymphatic malformation and may be associated with syndromes². We present a neonate with isolated congenital chylothorax. To best of our knowledge there are no published reports of CC in Sri Lanka.

Case Report

The antenatal scan of a 25-year-old primigravida mother was detected to have a right side pleural effusion in the fetus. An extensive anomaly scan by a specialist in fetal medicine at 34 weeks of gestation confirmed the finding without any other associated congenital abnormalities. The baby boy was delivered vaginally at term with a birth weight of 3.1kg and good Apgar scores. His routine newborn examination was unremarkable except for reduced air entry in the right lower zone.

An ultrasound scan (USS) of the chest on day two of life demonstrated a right (R) sided pleural effusion. He was not in respiratory distress and the oxygen saturations were normal. His chest X-ray revealed (R) sided pleural effusion with collapse of the right lung (Figure 1) although there was clinically no respiratory compromise in the baby.

On the tenth day of life the baby developed respiratory distress and repeat USS of chest revealed a massive pleural effusion. An intercostal (IC) tube was inserted on the same day and the fluid was

drained. The fluid was yellowish white in colour without blood staining which was in favour of chyle. (Figure 2)



Figure 1: (R) sided pleural effusion with collapse of (R) lung



Figure 2: Macroscopic appearance of pleural fluid

¹Teaching Hospital Karapitiya, Sri Lanka, ²Faculty of Medicine, University of Ruhuna, Sri Lanka, ³Teaching Hospital Mahamodara

*Correspondence: thilina4u@gmail.com

 [orcid.org/ 0000-0002-2502-6720](https://orcid.org/0000-0002-2502-6720)

(Received on 07 June 2018: Accepted after revision on 20 July 2018)

The authors declare that there are no conflicts of interest

Personal funding was used for the project.

Open Access Article published under the Creative

Commons Attribution CC-BY  License

The pleural fluid analysis confirmed chylothorax due to high triglyceride levels and low cholesterol levels. (Table 1) The intercostal tube was kept in situ for 7 days until cessation of the drain.

Table 1: Pleural fluid analysis

| | |
|----------------------|-----------------------------|
| Polymorphs | 4680 /cu mm |
| Lymphocytes | 10 /cu mm |
| Red cells | 205 /cu mm |
| Protein | 93 g/L |
| Lactic dehydrogenase | 93 U/L |
| Gram stain | Organisms nil |
| Culture | No growth |
| Cytology | No atypical/malignant cells |
| Fungal studies | Negative |
| Triglyceride | 118 mg/dl |

The baby was monitored for possible complications associated with chylothorax such as lymphopenia and hypoalbuminaemia. However, his lymphocyte count and serum albumin level remained within normal range. His basic biochemical investigations and inflammatory markers were normal. Serum cholesterol level was 18 mg/dl. His serum lactic dehydrogenase (LDH) was 625 U/L (0-248) and serum protein was 58 g/L (41-63). 2D-echocardiography revealed good biventricular functions and no pericardial fluid was noted.

The baby was kept nil oral and given intravenous (IV) fluid for 48 hours. He was commenced on medium chain fatty acid rich formula continued for 10 days. IV octreotide 1µg/kg/hr infusion was initiated and tailed off over a 9 days. The IC tube was kept in situ for 5 days and was removed 2 days later after drain became nil. The baby was commenced on breast feeding on day 21 and discharged after 2 weeks of hospital stay. He did not have any respiratory distress on discharge and repeat USS of the chest showed no effusion.

Discussion

The mortality rate of CC ranges from 20-60%¹. Iatrogenic trauma, malignancies and some granulomatous infections cause secondary chylothorax in infants and children^{1,2}. Antenatally detected CC can act as a space occupying lesion interrupting normal lung development³. Best method of diagnosing chylothorax is measurement of pleural fluid triglyceride and cholesterol levels⁴. If the triglyceride level is more than 110 mg/dl and the pleural fluid to serum cholesterol ratio is less than one, the diagnosis is established. Computerized

tomography scan, magnetic resonance imaging, lymphangiography and lymphoscintigraphy will be helpful as imaging studies to visualize the lymphatic system to identify chyle leak and lymphatic system anatomy⁴.

The key aims in treatment of chylothorax include relief of respiratory symptoms by draining the pleural fluid, treating the underlying cause to prevent recurrences and management of associated complications like malnutrition and immunodeficiency². Octreotide can be used to reduce the chyle production. It is thought to cause reduction in splanchnic circulation and thereby reduce chyle production^{5,6}. Failed medical management of chylothorax warrants surgical intervention. Surgical options include thoracic duct ligation, pleurodesis and pleuro-peritoneal shunt placement².

References

1. Krishnamurthy MB , Malhotra A. Congenital chylothorax: current perspectives and trends. *Research and Reports in Neonatology* 2017; 7: 53–63.
2. Tutor JD. Chylothorax in infants and children. *Pediatrics* 2014; 133(4): 722-33.
3. Soto-Martinez M, Massie J. Chylothorax: diagnosis and management in children. *Paediatric Respiratory Reviews* 2009;10(4):199–207
4. Light RW. Chylothorax and pseudochylothorax. In: *Pleural Diseases*, 6th ed. Philadelphia, PA: Wolters Kluwer Lippincott Williams and Wilkins; 2013
5. Kalomenidis I. Octreotide and chylothorax. *Current Opinion in Pulmonary Medicine* 2006; 12(4):264–7.
6. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the paediatric population. *American Journal of Therapeutics* 2001; 8(6):409–15.